PMID- 25022067
OWN - NLM
STAT- MEDLINE
DCOM- 20140815
LR  - 20151119
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 62
IP  - 4
DP  - 2014 Apr
TI  - [Companion diagnostics in the era of personalized medicine--chairmen's 
      introductory remarks].
PG  - 378-80
AB  - Personalized medicine is a medical model that proposes the customization of 
      treatment for individual patients. In this model, diagnostic tests are essential 
      for selecting safer and more efficacious treatments. The term "companion 
      diagnostics" has been used to describe these tests, whereby molecular assays that 
      measure the levels of proteins or specific gene mutations are used to provide a 
      specific therapy for an individual by stratifying the disease status, selecting 
      the proper medication, and tailoring dosages. Examples of companion diagnostics 
      in the field of cancer medicine for molecular targeted therapy include tests for 
      the ALK-fusion gene in non-small cell lung cancer and expression of CCR4 in adult 
      T-cell leukemia. For breast cancer, the expression of HER2 protein is evaluated 
      by immunohistochemistry (IHC), and gene amplification of HER2 is tested by 
      fluorescence in situ hybridization (FISH); both tests consist of pre-analysis, 
      analysis, and post-analysis processes that require quality control to ensure the 
      reliability of the results. This symposium includes: 1) future aspects of 
      companion diagnostics addressing many of the problems that must be overcome, 2) 
      companion diagnostics using FISH focusing on HER2 amplification and ALK 
      alteration, 3) newly developed diagnostic tests using tumor specimens and 
      cell-free DNA in serum, and 4) CCR4 expression detected by IHC and flow 
      cytometry.
FAU - Fukutsuka, Katsuhiro
AU  - Fukutsuka K
FAU - Takubo, Takayuki
AU  - Takubo T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/diagnosis/drug therapy/genetics
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/drug therapy/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Pathology, Molecular
MH  - *Precision Medicine/economics
MH  - Receptor, ErbB-2/genetics/metabolism
EDAT- 2014/07/16 06:00
MHDA- 2014/08/16 06:00
CRDT- 2014/07/16 06:00
PHST- 2014/07/16 06:00 [entrez]
PHST- 2014/07/16 06:00 [pubmed]
PHST- 2014/08/16 06:00 [medline]
PST - ppublish
SO  - Rinsho Byori. 2014 Apr;62(4):378-80.